Abstract | OBJECTIVE: BACKGROUND:
Bivalirudin is recommended for periprocedural use in patients undergoing PCI who are of high bleeding risk. However, its safe and efficacious use in elderly patients, a typical high bleeding risk cohort, in real world practice is yet to be reported. METHODS: In this single center, real-world observational study, 4736 consecutive elderly patients who underwent PCI were enrolled. Of these, 1240 were treated with bivalirudin and 3496 with heparin according to the periprocedural anticoagulation strategies of PCI. The primary outcome was 12-month net adverse clinical events (NACE) defined as a composite of cardiac death, myocardial infarction, stroke, revascularization, or any bleeding. Propensity score matching (PSM) was used to balance baseline characteristics between groups. RESULTS: After PSM, bivalirudin was found to be associated with lower rates of NACE (19.1% vs. 24.7%, p = 0.002), cardiac death (2.7% vs. 4.3%, p = 0.038), and any bleeding (10.0% vs. 12.9%, p = 0.023) compared to heparin monotherapy. No differences were found in the incidences of myocardial infarction, stroke, revascularization, stent thrombosis (0.1% vs. 0.1%, p = 1.000), and major bleedings (0.5% vs. 0.5%, p = 1.000) between the two patient groups. CONCLUSION:
|
Authors | Jing Li, Xiying Liu, Sicong Ma, Kun Na, Zizhao Qi, Ying Xu, Miaohan Qiu, Yaling Han, Yi Li |
Journal | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
(Catheter Cardiovasc Interv)
Vol. 99 Suppl 1
Pg. 1448-1455
(05 2022)
ISSN: 1522-726X [Electronic] United States |
PMID | 35077603
(Publication Type: Journal Article, Observational Study)
|
Copyright | © 2022 Wiley Periodicals LLC. |
Chemical References |
- Anticoagulants
- Hirudins
- Peptide Fragments
- Recombinant Proteins
- Heparin
- bivalirudin
|
Topics |
- Aged
- Anticoagulants
(adverse effects)
- Coronary Artery Disease
(complications, diagnostic imaging, therapy)
- Death
- Hemorrhage
(chemically induced)
- Heparin
(adverse effects)
- Hirudins
(adverse effects)
- Humans
- Myocardial Infarction
(complications)
- Peptide Fragments
(adverse effects)
- Percutaneous Coronary Intervention
(adverse effects)
- Recombinant Proteins
(adverse effects)
- Stroke
(etiology, prevention & control)
- Thrombosis
(etiology)
- Treatment Outcome
|